Home

search

Subjectguide
Journals
Books / Serials / Multimedia
Services
Services

Login for Subscribers
Logout

Sitemap
Help
Contacts


Logo






Vol. 67, Suppl. 1, 2007   

Free Abstract     Article (Fulltext)     Article (PDF 166 KB)     

Growth Hormone and Growth Factors in Endocrinology and Metabolism.
Editor(s): Koppeschaar, H.P.F. (Utrecht), Tuvemo, T. (Uppsala), Trainer, P. (Manchester), Zeitler, P. (Denver, Colo.)


KIGS Highlights

Hormonal Treatment of Idiopathic Short Stature
Edward O. Reiter

Tufts University School of Medicine, Baystate Children's Hospital, Springfield, Mass., USA

Address of Corresponding Author

Horm Res 2007;67 (Suppl. 1):58-63 (DOI: 10.1159/000097554)


 goto top of page Key Words

  • Growth hormone
  • Short stature
  • Insulin-like growth factor deficiency

 goto top of page Abstract

Background and Objective: The classification idiopathic short stature (ISS) represents a heterogeneous group of children who, as a group, are similar in height to patients with growth hormone (GH) deficiency, Turner syndrome, and short stature as a consequence of being born small for gestational age. GH therapy has been an effective treatment for enhancing height in children with ISS. Methods: A large body of literature - including data from KIGS (Pfizer International Growth Study Database) and the National Cooperative Growth Study database - shows that non-placebo-controlled GH treatment programs generally, though not uniformly, are associated with substantial increments in height gain. Placebo-controlled trials conducted in several countries report significant gains of 5 to 8 cm in final height. Conclusions: Long-term data are needed to assess the behavioral consequences, if any, of GH treatment for children with ISS. As the pool of children with ISS is potentially large, it would be highly desirable if clinical trials enabled accurate prediction of likely height gain and could result in greater individualization of treatment. The use of aromatase inhibitors to slow estrogen-mediated skeletal maturation is a new treatment modality, but it has only been minimally tested. The lower cost and ease of oral administration are attractive considerations, but long-term safety data are needed.

Copyright © 2007 S. Karger AG, Basel


 goto top of page Author Contacts

Edward O. Reiter, MD
Baystate Medical Center Children's Hospital
Tufts University School of Medicine
Springfield, MA 01199 (USA)
Tel. +1 413 794 5060, Fax +1 413 794 3623, E-Mail edward.reiter@bhs.org


 goto top of page Article Information

Published online: February 15, 2007
Number of Print Pages : 6
Number of Figures : 0, Number of Tables : 0, Number of References : 67

 
Journal Home
Journal Content
Guidelines
Editorial Board
Aims and Scope
Subscriptions
Medline Abstract (ID 17308401)
Download Citation



This journal is part of the third subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues


For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.




copyright  © 2009 S. Karger AG, Basel